Evidence map›Paper›PMID 1370874›Full record

ArticleAmerican journal of human genetics1992

Dominant negative and loss of function mutations of the c-kit (mast/stem cell growth factor receptor) proto-oncogene in human piebaldism.

R A Spritz, L B Giebel, S A Holmes

Abstract read
In one paragraph

Article in American journal of human genetics, 1992. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 159 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis.Proceedings of the National Academy of Sciences of the United States of America · 1999
    Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Mouse homologues of human hereditary disease.Journal of medical genetics · 1994
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

R A SpritzDepartment of Medical Genetics, University of Wisconsin, Madison.
L B Giebel
S A Holmes
University of Wisconsin–Madison · US

Funding

STUDIES OF HUMAN PIGMENTATION DISORDERSR01AR039892 · NIAMS · UNIVERSITY OF WISCONSIN MADISON · PI SPRITZ, RICHARD A · 1989 to 2005
$2.5M
NIAMS NIH HHS AR 39892
6 · The paper itself

Abstract

Piebaldism is an autosomal dominant disorder of melanocyte development and is characterized by congenital white patches of skin and hair from which melanocytes are completely absent. A similar disorder of the mouse, "dominant white spotting" (W), results from mutations of the c-kit proto-oncogene, which encodes the cellular tyrosine kinase receptor for the mast/stem cell growth factor. We have identified c-kit gene mutations in three patients with piebaldism. A missense substitution (Phe----Leu) at codon 584, within the tyrosine kinase domain, is associated with a severe piebald phenotype, whereas two different frameshifts, within codons 561 and 642, are both associated with a variable and relatively mild piebald phenotype. This is consistent with a possible "dominant negative" effect of missense c-kit polypeptides on the function of the dimeric receptor.

Indexed as

Genes, DominantMutationProto-OncogenesAmino Acid SequenceBase SequenceBlotting, SouthernFemaleGenetic LinkageHeterozygoteHumansMaleMolecular Sequence DataPedigreePiebaldismPolymerase Chain ReactionPolymorphism, GeneticMAS1 protein, humanProto-Oncogene MasProto-Oncogene ProteinsProto-Oncogene Proteins c-kit

Identifiers

PMID1370874
PMCPMC1682440
OpenAlexW1560994819

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.